Optimization of budesonide compression-coated tablets for colonic delivery

AAPS PharmSciTech

Volumn 10, Issue 1, 2009, Pages 147-157

  Yehia, Soad A ^a   Elshafeey, Ahmed H ^a   Sayed, Ibrahim ^a   Shehata, Ahmed H ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

Budesonide; Colon targeting; Compression coat; Guar gum; Pectin; Tablets; TNBS induced rabbit colitis

Indexed keywords

BUDESONIDE; CELLABURATE; EUDRAGIT; GUAR GUM; HYDROXYPROPYLMETHYLCELLULOSE; MYELOPEROXIDASE; PECTIN; ANTIINFLAMMATORY AGENT; CELLULOSE; CELLULOSE ACETATE-BUTYRATE; DRUG CARRIER; DRUG DERIVATIVE; GALACTAN; GASTROINTESTINAL AGENT; MANNAN; METHYLCELLULOSE; METHYLMETHACRYLATE METHACRYLIC ACID COPOLYMER; METHYLMETHACRYLATE-METHACRYLIC ACID COPOLYMER; PLANT GUM; POLYMETHACRYLIC ACID DERIVATIVE; TRINITROBENZENESULFONIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COLITIS; CONNECTIVE TISSUE CELL; CONTROLLED RELEASE FORMULATION; DRUG COATING; DRUG DELIVERY SYSTEM; ENZYME ACTIVITY; EXPERIMENTAL RABBIT; IN VITRO STUDY; INFLAMMATORY CELL; MALE; NONHUMAN; ORGAN WEIGHT; PH; PROCESS OPTIMIZATION; RAT; REACTION TIME; TABLET COMPRESSION; TARGET ORGAN; TISSUE SPECIFICITY; ANIMAL; CHEMICALLY INDUCED DISORDER; CHEMISTRY; COLON; DELAYED RELEASE FORMULATION; DIFFERENTIAL SCANNING CALORIMETRY; DISEASE MODEL; DRUG EFFECT; DRUG FORMULATION; ENTERIC COATED TABLET; ENZYMOLOGY; FLOW KINETICS; KINETICS; METABOLISM; METHODOLOGY; ORAL DRUG ADMINISTRATION; PATHOLOGY; PHARMACEUTICS; RABBIT; SOLUBILITY;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS; BUDESONIDE; CALORIMETRY, DIFFERENTIAL SCANNING; CELLULOSE; CHEMISTRY, PHARMACEUTICAL; COLITIS; COLON; DELAYED-ACTION PREPARATIONS; DISEASE MODELS, ANIMAL; DRUG CARRIERS; DRUG COMPOUNDING; GALACTANS; GASTROINTESTINAL AGENTS; HYDROGEN-ION CONCENTRATION; KINETICS; MALE; MANNANS; METHYLCELLULOSE; PECTINS; PLANT GUMS; POLYMETHACRYLIC ACIDS; RABBITS; RHEOLOGY; SOLUBILITY; TABLETS, ENTERIC-COATED; TECHNOLOGY, PHARMACEUTICAL; TRINITROBENZENESULFONIC ACID;

EID: 67549105892     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-009-9188-3     Document Type: Article

References (32)

1. M. K. Chourasia, and S. K. Jain. Pharmaceutical approaches to colon targeted drug delivery systems. J. Pharm. Pharm. Sci. 6:33-66 (2003).
2. A. W. Basit. Advances in colonic drug delivery. Drugs. 6514:1991-2007 (2005).
3. A. Jain, Y. Gupta, and S. K. Jain. Azo-chemistry and its potential for colonic delivery. Crit. Rev. Ther. Drug Carrier Syst. 25:349-400 (2006).
4. G. L. Simon, and S. L. Gorbach. The human intestinal microflora. Dig. Dis. Sci. 319 Suppl:147S-162S (1986).
5. S. L. Gorbach. Intestinal microflora. Gastroenterology. 606:1110-1129 (1971).
6. A. Rubinstein. Microbially controlled drug delivery to the colon. Biopharm. Drug Dispos. 116:465-475 (1990).
7. V. R. Sinha, and R. Kumria. Polysaccharides in colon-specific drug Delivery. Int. J. Pharm. 224:19-38 (2001).
8. V. R. Sinha, and R. Kumria. Microbially triggered drug delivery to the colon. Eur. J. Pharm. Sci. 18:3-18 (2003).
9. L. S. Liu, M. L. Fishman, J. Kost, and K. B. Hicks. Pectin-based systems for colon-specific drug delivery via oral route. Biomaterials. 24:3333-3343 (2003).
10. S. A. Johansson, K. E. Andersson, R. Brattsand, E. Gruvstad, and P. Hedner. Topical and systemic glucocorticoid potencies of budesonide, beclomethasone dipropionate and prednisolone in man. Eur. J. Respir. Dis. Suppl. 122:74-82 (1982).
11. S. Edsbacker, P. Wollmer, A. Nilsson, and M. Nilsson. Pharmacokinetics and gastrointestinal transit of budesonide controlled ileal release (CIR) capsules. Gastroenterology. 104:695 (1993).
12. Y. Krishnamachari, P. Madan, and S. Lin. Development of pH- and time-dependent oral microparticles to optimize budesonide delivery to ileum and colon. Int. J. Pharm. 338:238-247 (2007).
13. M. Rodriguez, J. A. Antunez, C. Taboada, B. Seijo, and D. Torres. Colon-specific delivery of budesonide from microencapsulated cellulosic cores: Evaluation of the efficacy against colonic inflammation in rats. J. Pharm. Pharmacol. 53:1207-1215 (2001).
14. Y. Ozeki, Y. Kondo, Y. Watanabe, K. Shimada, K. Harada. Rotary type compression molding machine. PCT WO02/90098, 14 November (2002).
15. P. E. Luner, L. E. Kirsch, S. Majuru, E. Oh, A. B. Joshi, D. E. Wurster, and M. P. Redmon. Preformulation studies on the S-isomer of oxybutynin hydrochloride, an Improved Chemical Entity (ICE). Drug Dev. Ind. Pharm. 274:321-329 (2001).
16. R. L. Carr. Classifying flow properties of solids. Chem. Eng. 72:69-72 (1964).
17. H. H. Hausner. Friction condition in a mass of metal powders. Int. J. Powder Metall. 3:7-13 (1967).
18. M. Turkoglu, and T. Ugurlu. In vitro evaluation of pectin-HPMC compression coated 5-aminosalicylic acid tablets for colonic delivery. Eur. J. Pharm. Biopharm. 531:65-73 (2002).
19. D. Wong, S. Larrabee, K. Clifford, J. Tremblay, and D. Friend. USP dissolution apparatus III (reciprocating cylinder) for screening of guar-based colonic delivery formulations. J. Control. Release. 47:173-179 (1997).
20. P. L. Ritger, and N. A. Peppas. A simple equation for description of solute release II. Fickian and anomalous release from swellable devices. J. Control. Release. 5:7-42 (1987).
21. N. A. Peppas, and J. J. Sahlin. A simple equation for the description of solute release. III. Coupling of diffusion and relaxation. Int. J. Pharm. 573:169-172 (1989).
22. J. Siepmann, and N. A. Peppas. Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Adv. Drug Deliv. Rev. 482-3:139-157 (2001).
23. H. Kim, and R. Fassihi. Application of a binary polymer system in drug release rate modulation. 1. Characterization of release mechanism. J. Pharm. Sci. 863:316-322 (1997).
24. W. H. Percy, M. B. Burton, F. Fallick, and R. Burakoff. A comparison in vitro of human and rabbit distal colonic muscle responses to inflammatory mediators. Gastroenterology. 99:1324-1332 (1990).
25. I. Depoortere, G. Van Assche, T. Thijs, K. Geboes, and T. L. Peeters. Differential changes in ACh-, motilin-, substance P-, and K(+)-induced contractility in rabbit colitis. Am. J. Physiol. 2771 Pt 1:G61-G68 (1999).
26. N. Cui, D. R. Friend, and R. N. Fedorak. A budesonide prodrug accelerates treatment of colitis in rats. Gut. 3510:1439-1446 (1994).
27. H. Sekizaki, K. Danjo, H. Eguchi, Y. Yonesawa, H. Sunada, and A. Otsuka. Solid-state interaction of ibuprofen with polyvinylpyrrolidone. Chem. Pharm. Bull. 436:988-993 (1995).
28. J. I. Wells. Pharmaceutical preformulation: The physicochemical properties of drug substances, Elis Horwood, Chichester, UK, 1988, p. 86.
29. M. E. Sangalli, A. Maroni, A. Foppoli, L. Zema, F. Giordano, and A. Gazzaniga. Different HPMC viscosity grades as coating agents for an oral time and/or site-controlled delivery system: A study on process parameters and in vitro performances. Eur. J. Pharm. Sci. 225:469-476 (2004).
30. J. M. Llabot, R. H. Manzo, and D. A. Allemandi. Drug release from carbomer: carbomer sodium salt matrices with potentialnext term use as previous termmucoadhesive drug delivery system. Int. J. Pharm. 2761-2:59-66 (2004).
31. A. M. Goldsten, E. N. Alter, and J. K. Seaman. Guar gum. In R. L. Whistler (ed.), Oral colon specific drug delivery and their derivatives, Academic, Florida, pp. 1-43 (1992).
32. T. Durig, and R. Fassihi. Guar-based monolithic matrix systems: Effect of ionizable and non-ionizable substances and excipients on gel dynamics and release kinetics. J. Control. Release. 80:45-56 (2002).